DAMORA THERAPEUTICS, INC.: research and development expense
Research and development expense for DAMORA THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All DAMORA THERAPEUTICS, INC. financial histories
What this measure means
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
Exact concept: us-gaap:ResearchAndDevelopmentExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 26,877,000 | USD | 2026-03-19 | 10-K · 0001193125-26-115922 |
| 2024-01-01 | 2024-12-31 | 6,398,000 | USD | 2026-03-19 | 10-K · 0001193125-26-115922 |
| 2023-01-01 | 2023-12-31 | 23,770,000 | USD | 2025-03-19 | 10-K · 0000950170-25-041981 |
| 2022-01-01 | 2022-12-31 | 48,206,000 | USD | 2024-03-08 | 10-K · 0000950170-24-028610 |
| 2021-01-01 | 2021-12-31 | 38,488,000 | USD | 2023-03-09 | 10-K · 0000950170-23-006807 |
| 2020-01-01 | 2020-12-31 | 24,627,000 | USD | 2022-02-17 | 10-K · 0001564590-22-005569 |
| 2019-01-01 | 2019-12-31 | 19,738,000 | USD | 2021-03-29 | 10-K · 0001564590-21-015916 |
Related financial histories
- DAMORA THERAPEUTICS, INC.: total assets
- DAMORA THERAPEUTICS, INC.: total liabilities
- DAMORA THERAPEUTICS, INC.: stockholders equity
- DAMORA THERAPEUTICS, INC.: cash and cash equivalents
- DAMORA THERAPEUTICS, INC.: net income or loss
- DAMORA THERAPEUTICS, INC.: operating cash flow
- DAMORA THERAPEUTICS, INC.: financing cash flow
- DAMORA THERAPEUTICS, INC.: investing cash flow
- DAMORA THERAPEUTICS, INC.: retained earnings or deficit
- DAMORA THERAPEUTICS, INC.: basic weighted-average shares
- DAMORA THERAPEUTICS, INC.: diluted weighted-average shares
- DAMORA THERAPEUTICS, INC.: basic earnings per share
- DAMORA THERAPEUTICS, INC.: diluted earnings per share
- DAMORA THERAPEUTICS, INC.: income tax expense or benefit
- DAMORA THERAPEUTICS, INC.: net property, plant and equipment
- DAMORA THERAPEUTICS, INC.: share-based compensation expense
- DAMORA THERAPEUTICS, INC.: operating income or loss
- DAMORA THERAPEUTICS, INC.: current assets
- DAMORA THERAPEUTICS, INC.: current liabilities
- DAMORA THERAPEUTICS, INC.: current accounts payable
- DAMORA THERAPEUTICS, INC.: operating expenses
Inspect the source
- Entity
- DAMORA THERAPEUTICS, INC. / CIK 0001800315
- Captured
- 2026-09-21T17:27:56.301Z
- SEC response SHA-256
679f923739e1cb631c01938e3cd336db62cb93da6ab104658dec60d8685350e4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001800315.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))